Nanobiotix updates on JNJ-1900 (NBTXR3) trials, FDA-cleared protocol change, and cash into 2029

Nanobiotix released its first half 2026 operational and financial update on September 24, 2026, highlighting fresh clinical data and a regulatory change across its JNJ-1900 (NBTXR3) programs.

In the Phase 1 study sponsored by UT MD Anderson Cancer Center in inoperable, locoregionally recurrent non-small cell lung cancer, at a median follow-up of 12 months, the one-year locoregional control rate was 79%, one-year local progression-free survival was 61%, and one-year overall survival was 70% in evaluable patients.¹ All 24 patients finished the JNJ-1900 (NBTXR3) plus re-irradiation regimen without any dose-limiting toxicities, and no related Grade 3 or higher adverse events occurred, with the recommended Phase 2 dose set at 33% of gross tumor volume.¹

In the Johnson & Johnson-led Phase 2 CONVERGE study in Stage 3 unresectable NSCLC, data updated at ESTRO 2026 showed an overall response rate of 85.7% (6 of 7 patients) and a complete response rate of 57.1% (4 of 7 patients), compared with an earlier ORR of 71.4% (5 of 7 patients) reported at ELCC 2026 in the same cohort.¹ The company said the procedure showed an acceptable safety profile without serious treatment-emergent adverse events.¹

The FDA cleared a protocol amendment to the Phase 3 NANORAY-312 study in cisplatin-ineligible head and neck cancer. The amendment eliminated the previously planned interim analysis and modified the final analysis to require fewer events, moving it up in timing.¹

On financing, Nanobiotix closed a global follow-on offering with the underwriters' over-allotment option fully exercised, bringing total gross proceeds to about €86 million.¹ Cash and cash equivalents reached €110.9 million as of June 30, 2026, up from €52.8 million at the end of 2025.¹ The company said this cash position is expected to fund operations into 2029.¹